Ventfort
Research OnlyAlso known as: Vascular cytamin, Blood vessel peptides, A-14 vascular peptides
A cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for vascular health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Research Statistics
Russian bioregulator (Khavinson lab); minimal published research. Animal-only data from Russian Institute of Bioregulation. No human trials, no Western replication. Vascular tissue bioregulation mechanism is theoretical.
Research Dossier
Overview
What is Ventfort and what does the research say?
Mechanism of Action
Ventfort is a cytamin-class supplement containing peptide complexes derived from blood vessel tissue.
Proposed Mechanisms
- Endothelial Support - Claimed to support blood vessel lining function
- Vascular Tone - Proposed effects on vessel elasticity
- Cardiovascular Health - Marketed for overall vascular support
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials
- NOT a treatment for cardiovascular disease
- Not approved by any Western regulatory agency
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
Peptide Interactions
Known and theoretical interactions when combining Ventfort with other peptides. Based on published research and mechanistic considerations.
Vesugen
CompatibleBoth target vascular function - Vesugen is synthetic KED tripeptide, Ventfort is tissue-derived cytamin supplement.
Cardiogen
CompatibleBoth target cardiovascular system - Cardiogen for heart, Ventfort for blood vessels.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ventfort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.